Galantamine in the treatment of vascular dementia

International Psychogeriatrics

Volumn 15, Issue SUPPL. 1, 2003, Pages 187-193

  Brashear, H Robert ^a,b,c  

^a UNIVERSITY OF VIRGINIA   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Cerebrovascular; Cholinesterase inhibitor; Cognitive impairment; Multi infarct

Indexed keywords

CHOLINERGIC RECEPTOR; CHOLINESTERASE INHIBITOR; GALANTAMINE; NICOTINIC RECEPTOR; PLACEBO;

AGED; ALZHEIMER DISEASE; CEREBROVASCULAR DISEASE; CHOLINESTERASE INHIBITION; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DIFFERENTIAL DIAGNOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; MULTIINFARCT DEMENTIA; NAUSEA; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VOMITING;

EID: 0141819867     PISSN: 10416102     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1041610203009189     Document Type: Conference Paper

References (29)

1. Bullock, R., & Lilienfeld, S. (2001). Galantamine shows promising results in probable vascular dementia and Alzheimer's disease with cerebrovascular components. Poster presented at the XVII World Congress of Neurology, London, UK.
2. Chui, H., & Gonthier, R. (1999). Natural history of vascular dementia. Alzheimer Disease and Associated Disorders 13(Suppl. 3), S124-S130.
3. Doody, R. S., & Kershaw, P. (2001). The cognitive benefits of galantamine are sustained for at least 24 months: Results of a long-term extension trial in Alzheimer's disease. Neurology, 56(Suppl. 3), A456.
4. Erkinjuntti, T. (2001a). Cerebrovascular dementia: Pathophysiology, diagnosis, and treatment. CNS Drugs, 12, 35-48.
5. Erkinjuntti, T. (2001b). Clinical deficits of Alzheimer's disease with cerebrovascular disease and probable VaD. International Journal of Clinical Practice, 120(Suppl.), 14-23.
6. Erkinjuntti, T., Kurz, A., Gauthier, S., Bullock, R., et al. (2002). Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: A randomised trial. Lancet, 359, 1283-1290.
7. Evans, D. A., Funkenstein, H. H., Albert, M. S., et al. (1989). Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. Journal of the American Medical Association, 262, 2551-2556.
8. Gold, G., Giannakopoulos, P., Montes-Paixao, J. C., et al. (1997). Sensitivity and specificity of newly proposed clinical criteria for possible vascular dementia. Neurology, 49, 690-694.
9. Gottfries, C. G., Blennow, K., Karlsson, I., & Wallin, A. (1994). The neurochemistry of vascular dementia. Dementia, 5, 163-167.
10. Kalaria, R. N., & Ballard, C. (1999). Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Disease and Associated Disorders, 13(Suppl. 3), S115-S123.
11. Kimura, S., Saito, H., Minami, M., et al. (2000). Pathogenesis of vascular dementia in stroke-prone spontaneously hypertensive rats. Toxicology, 153, 167-178.
12. Kittner, B. (1999). Clinical trials of propentofylline in vascular dementia. European/Canadian Propentofylline Study Group. Alzheimer Disease and Associated Disorders, 13(Suppl. 3), S166-S171.
13. Kumar, V., Anand, R., Messina, J., Hartman, R., & Veach, J. (2000). An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. European Journal of Neurology, 7, 159-169.
14. McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price D., et al. (1984). Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology, 34, 939-944.
15. Mendez, M. F., Younesi, F. L., & Perryman, K. M. (1999). Use of donepezil for vascular dementia: Preliminary clinical experience. Journal of Neuropsychiatry and Clinical Neuroscience, 11, 268-270.
16. Moretti, R., Torre, P., Antonello, R. M., & Cazzato, G. (2001). Rivastigmine in subcortical vascular dementia: A comparison trial on efficacy and tolerability for 12 months follow-up. European Journal of Neurology, 8, 361-362.
17. Raskind, M. A., Peskind, E. R., Wessel, T., & Yuan, W. (2000). Galantamine in AD: A 6-month randomized, placebo controlled trial with a 6-month extension. Neurology, 54, 2261-2268.
18. Rockwood, K., Mintzer, J., Truyen, L., Wessel, T., & Wilkinson, D. (2001). Effects of a flexible galantamine dose in Alzheimer's disease: A randomised, controlled trial. Journal of Neurology, Neurosurgery, and Psychiatry, 71, 589-595.
19. Rockwood, K., Wentzel, C., Hachinski, V., Hogan, D. B., MacKnight, C., et al. (2000). Prevalence and outcomes of vascular cognitive impairment. Vascular Cognitive Impairment Investigators of the Canadian Study of Health and Aging. Neurology, 54, 447-451.
20. Roman, G. C., Tatemichi, T. K., Erkinjuntti, T., et al. (1993). Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology, 43, 250-260.
21. Saito, H., Togashi, H., Yoshioka, M., Nakamura, N., Minami, M., & Parvez, H. (1995). Animal models of vascular dementia with emphasis on stroke-prone spontaneously hypertensive rats. Clinical and Experimental Pharmacology and Physiology, 22(Suppl. 1), S257-S259.
22. Samochocki, M., Zerlin, M., Jostock, R., Groot Kormelink, P. J., Luyten, W. H., et al. (2000). Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR. Acta Neurologica Scandinavica, 176(Suppl.), 68-73.
23. Selden, N. R., Gitelman, D. R., Salamon-Murayama, N., Parrish, T. B., & Mesulam, M. M. (1998). Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain. Brain, 121(Pt. 12), 2249-2257.
24. Tariot, P. N., Solomon, P. R., Morris, J. C., Kershaw, P., Lilienfeld, S., et al. (2000). A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology, 54, 2269-2276.
25. Togashi, H., Kimura, S., Matsumoto, M., Yoshioka, M., Minami, M., & Saito, H. (1996). Cholinergic changes in the hippocampus of stroke-prone spontaneously hypertensive rats. Stroke, 27, 520-525.
26. Togashi, H., Matsumoto, M., Yoshioka, M., Hirokami, M., Minami, M., et al. (1994). Neurochemical profiles in cerebrospinal fluid of stroke-prone spontaneously hypertensive rats. Neuroscience Letters, 166, 117-120.
27. Tohgi, H., Abe, T., Kimura, M., Saheki, M., & Takahashi, S. (1996). Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer's-type dementia. Journal of Neural Transmission, 103, 1211-1220.
28. Wilcock, G., Stoeffer, A., Sahin, K., & Moebius, H. J. (2000a). Neuro-radiological findings and the magnitude of cognitive benefit by memantine treatment: A subgroup analysis of two placebo-controlled clinical trials in vascular dementia. European Neuropsychopharmacology, 10(Suppl. 3), S360.
29. Wilcock, G. K., Lilienfeld, S., & Gaens, E. (2000b). Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial. British Medical Journal, 321, 1445-1449.